Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CMX-2043, a multi-modal cytoprotective compound based on a naturally-occurring molecule present in the human body, has previously demonstrated safety and efficacy in preclinical models of TBI.
Lead Product(s): CMX-2043
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CMX-2043
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: US Department of Defense
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2021